Stereotactic Body Radiotherapy for Pancreatic Cancer

Full Article

CL Chiang, CSY Yeung, MYP Wong, VWY Lee, VHF Lee, FAS Lee, FCS Wong

Hong Kong J Radiol 2017;20:303-11

DOI: 10.12809/hkjr1716861

Despite advances in surgical, radiation and systemic therapy, the prognosis of pancreatic cancer remains poor. Most patients are not amendable to curative surgical resection at presentation. Chemo-radiotherapy is the standard of care for locally advanced pancreatic cancer, but its local control is poor. Stereotactic body radiotherapy (SBRT) is a viable therapeutic option to maximise local control with a tolerable side-effect profile. It enables precise delivery of high-dose radiation over a short period (typically 1-5 days) and leads to better local control, disease outcome, and symptom palliation. SBRT can also be applied in neoadjuvant, adjuvant, or re-irradiation treatment. We review the technology, clinical application, and future direction of SBRT for treatment of pancreatic cancer.


Authors' affiliations:
CL Chiang1,2,3, CSY Yeung3, MYP Wong4, VWY Lee3, VHF Lee1,2, FAS Lee3, FCS Wong3

1Department of Clinical Oncology, The University of Hong Kong, Pokfulam, Hong Kong
2Department of Clinical Oncology, The University of Hong Kong–Shenzhen Hospital, Shenzhen, China
3Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong
4Department of Medical Physics, Tuen Mun Hospital, Tuen Mun, Hong Kong